Neoprobe Forms Collaborative Agreement With Zurich Researcher; Dr. Gregor Zund Joins Advisory Board.

Business Editors/Health/Medical Writers

DUBLIN, Ohio--(BUSINESS WIRE)--Dec. 18, 2003

Neoprobe Corporation (OTCBB:NEOP), today announced that Dr. Gregor Zund, the head of the renowned cardiovascular research group at the University of Zurich, has joined the vascular advisory board of Neoprobe to assist in the development and commercialization of Neoprobe's blood flow technology (Quantix(TM) products). Dr. Zund is the Head of the Division of Surgical Research at the University Hospital Zurich. The department of surgical research is a fifty person multi-disciplinary organization specializing in cardiac, vascular, transplant and trauma surgery. Surgeons within the group have been evaluating the Quantix systems in a variety of clinical settings.

Dr. Zund said, "I feel honored to join the advisory board at Neoprobe to assist in the development and commercialization of the Cardiosonix' blood flow technology. It is essential for cardiac and vascular surgeons to have the opportunity to measure peri- and postoperatively blood flow in vascular bypass-grafts. With such blood flow measurements, the morbidity and mortality rate of cardio-vascular procedures will be significantly decreased. Furthermore, blood flow measurement products like Quantix will give surgeons the opportunity to perform standardized quality controls and to realize early and late failures."

David Bupp, Neoprobe's President and CEO, said, "We are delighted to have an outstanding researcher and thought leader like Dr. Zund join the vascular advisory team of Neoprobe. Dr. Zund and his team at the University of Zurich will help realize the potential of the Quantix blood flow measurement products."

About Neoprobe

Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe's current line of gamma detection systems is widely used for intraoperative lymphatic mapping (ILM), an emerging standard of care technology for breast cancer and melanoma. Neoprobe also holds significant interests in the development of related biomedical systems and agents. The Company's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. With the acquisition of Cardiosonix Ltd. in 2001, Neoprobe expanded its product portfolio to include blood flow measurement products. Cardiosonix is a development stage company that has recently received regulatory clearance to begin the clinical evaluation and commercial sale of its blood flow measurement products. Cardiosonix' products (the Quantix/ND(TM) and the Quantix/OR(TM)) are designed to be used by neurosurgeons, cardiovascular surgeons and critical care physicians.

Statements in this news release which relate to other than strictly historical facts are forward-looking statements, and as such are subject to risks and uncertainties, including those detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

www.neoprobe.com